Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan ; volume:30 ; number:4 ; day:22 ; month:5 ; year:2023 ; pages:657-665 ; date:7.2023
Breast cancer ; 30, Heft 4 (22.5.2023), 657-665, 7.2023
- Creator
-
Nozawa, K.
Terada, M.
Onishi, M.
Ozaki, Y.
Takano, T.
Fakhouri, W.
Novick, D.
Haro, J. M.
Faris, L. H.
Kawaguchi, T.
Tanizawa, Y.
Tsurutani, Junji
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12282-023-01461-6
- URN
-
urn:nbn:de:101:1-2023092210001452458726
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nozawa, K.
- Terada, M.
- Onishi, M.
- Ozaki, Y.
- Takano, T.
- Fakhouri, W.
- Novick, D.
- Haro, J. M.
- Faris, L. H.
- Kawaguchi, T.
- Tanizawa, Y.
- Tsurutani, Junji
- SpringerLink (Online service)
Other Objects (12)
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort
RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort
RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort
RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer